Repro Med Systems Stock Analysis

KRMD Stock  USD 2.81  0.14  4.75%   
Repro Med Systems is undervalued with Real Value of 3.6 and Target Price of 4.9. The main objective of Repro Med stock analysis is to determine its intrinsic value, which is an estimate of what Repro Med Systems is worth, separate from its market price. There are two main types of Repro Med's stock analysis: fundamental analysis and technical analysis.
The Repro Med stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Repro Med's ongoing operational relationships across important fundamental and technical indicators.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Repro Med Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

Repro Stock Analysis Notes

About 51.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.13. Repro Med Systems had not issued any dividends in recent years. KORU Medical Systems, Inc. designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York. Koru Medical operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 77 people. To find out more about Repro Med Systems contact Linda Tharby at 800 624 9600 or learn more at https://www.korumedical.com.

Repro Med Quarterly Total Revenue

8.84 Million

Repro Med Systems Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Repro Med's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Repro Med Systems or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Repro Med Systems generated a negative expected return over the last 90 days
Repro Med Systems has high historical volatility and very poor performance
The company reported the previous year's revenue of 33.65 M. Net Loss for the year was (6.07 M) with profit before overhead, payroll, taxes, and interest of 21.33 M.
Repro Med Systems currently holds about 18.27 M in cash with (319.72 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41.
Latest headline from thelincolnianonline.com: KORU Medical Systems, Inc. Sees Significant Increase in Short Interest

Repro Med Systems Upcoming and Recent Events

13th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
13th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Repro Largest EPS Surprises

Earnings surprises can significantly impact Repro Med's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2025-03-13
2024-12-31-0.0233-0.020.003314 
2019-04-30
2019-03-310.010.01960.009696 
2024-03-13
2023-12-31-0.04-0.030.0125 
View All Earnings Estimates

Repro Med Environmental, Social, and Governance (ESG) Scores

Repro Med's ESG score is a quantitative measure that evaluates Repro Med's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Repro Med's operations that may have significant financial implications and affect Repro Med's stock price as well as guide investors towards more socially responsible investments.

Repro Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
White Pine Capital Llc2024-12-31
157.9 K
State Street Corp2024-12-31
135.6 K
Washington Trust Co2024-12-31
100 K
Pnc Financial Services Group Inc2024-12-31
97 K
Empire Financial Management Company, Llc2024-12-31
95 K
683 Capital Management Llc2024-12-31
88.2 K
Morgan Stanley - Brokerage Accounts2024-12-31
86.3 K
Goldman Sachs Group Inc2024-12-31
83.9 K
Northern Trust Corp2024-12-31
79.2 K
First Light Asset Management, Llc2024-12-31
5.9 M
Topline Capital Management Llc2024-12-31
4.3 M
Note, although Repro Med's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Repro Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 129.14 M.

Repro Profitablity

The company has Profit Margin (PM) of (0.18) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.18) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.18.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.23)(0.22)
Return On Capital Employed(0.28)(0.26)
Return On Assets(0.22)(0.21)
Return On Equity(0.36)(0.34)

Management Efficiency

Repro Med Systems has return on total asset (ROA) of (0.1447) % which means that it has lost $0.1447 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3265) %, meaning that it created substantial loss on money invested by shareholders. Repro Med's management efficiency ratios could be used to measure how well Repro Med manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.22. The current year's Return On Capital Employed is expected to grow to -0.26. At present, Repro Med's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 20.1 M, whereas Other Current Assets are forecasted to decline to about 513.3 K.
Last ReportedProjected for Next Year
Book Value Per Share 0.37  0.39 
Tangible Book Value Per Share 0.35  0.37 
Enterprise Value Over EBITDA(30.67)(29.14)
Price Book Value Ratio 10.49  11.01 
Enterprise Value Multiple(30.67)(29.14)
Price Fair Value 10.49  11.01 
Enterprise Value170.5 M179 M
Repro Med Systems has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Operating Margin
(0.18)
Profit Margin
(0.18)
Beta
0.737
Return On Assets
(0.14)
Return On Equity
(0.33)

Technical Drivers

As of the 23rd of March, Repro Med holds the Coefficient Of Variation of (746.00), variance of 17.16, and Risk Adjusted Performance of (0.11). Repro Med Systems technical analysis gives you tools to exploit past prices in attempt to determine a pattern that determines the direction of the company's future prices. Please check Repro Med Systems information ratio and potential upside to decide if Repro Med Systems is priced some-what accurately, providing market reflects its current price of 2.81 per share. Please also confirm Repro Med Systems jensen alpha, which is currently at (0.44) to check out the company can sustain itself at a future point.

Repro Med Systems Price Movement Analysis

Execute Study
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Repro Med middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Repro Med Systems. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Repro Med Systems Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Repro Med insiders, such as employees or executives, is commonly permitted as long as it does not rely on Repro Med's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Repro Med insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Repro Med Outstanding Bonds

Repro Med issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Repro Med Systems uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Repro bonds can be classified according to their maturity, which is the date when Repro Med Systems has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Repro Med Predictive Daily Indicators

Repro Med intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Repro Med stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Repro Med Corporate Filings

F4
21st of March 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
12th of March 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
14th of February 2025
Other Reports
ViewVerify
F4
7th of February 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
21st of January 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
13th of January 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
3rd of January 2025
Other Reports
ViewVerify
13A
14th of November 2024
An amended filing to the original Schedule 13G
ViewVerify

Repro Med Forecast Models

Repro Med's time-series forecasting models are one of many Repro Med's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Repro Med's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Repro Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Repro Med prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Repro shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Repro Med. By using and applying Repro Stock analysis, traders can create a robust methodology for identifying Repro entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(0.18)(0.17)
Operating Profit Margin(0.17)(0.16)
Net Loss(0.18)(0.17)
Gross Profit Margin 0.63  0.46 

Current Repro Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Repro analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Repro analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
4.9Strong Buy5Odds
Repro Med Systems current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Repro analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Repro stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Repro Med Systems, talking to its executives and customers, or listening to Repro conference calls.
Repro Analyst Advice Details

Repro Stock Analysis Indicators

Repro Med Systems stock analysis indicators help investors evaluate how Repro Med stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Repro Med shares will generate the highest return on investment. By understating and applying Repro Med stock analysis, traders can identify Repro Med position entry and exit signals to maximize returns.
Begin Period Cash Flow11.5 M
Total Stockholder Equity16.8 M
Capital Lease Obligations3.7 M
Property Plant And Equipment Net7.3 M
Cash And Short Term Investments9.6 M
Net Invested Capital17.1 M
Cash9.6 M
50 Day M A3.8224
Net Interest Income444.6 K
Total Current Liabilities7.2 M
Forward Price Earnings188.6792
Investments-1.3 M
Stock Based Compensation2.6 M
Common Stock Shares Outstanding45.8 M
Tax Provision2893.00
Quarterly Earnings Growth Y O Y-0.66
Free Cash Flow-1.6 M
Other Current Assets749.9 K
Accounts Payable1.6 M
Net Debt-5.9 M
Other Operating Expenses39.2 M
Non Current Assets Total8.1 M
Liabilities And Stockholders Equity27.2 M
Non Currrent Assets Other99 K

Complementary Tools for Repro Stock analysis

When running Repro Med's price analysis, check to measure Repro Med's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repro Med is operating at the current time. Most of Repro Med's value examination focuses on studying past and present price action to predict the probability of Repro Med's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repro Med's price. Additionally, you may evaluate how the addition of Repro Med to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios